GlaxoSmithKline’s (GSK) Neutral Rating Reaffirmed at JPMorgan Chase & Co.
GlaxoSmithKline (NYSE:GSK)‘s stock had its “neutral” rating reaffirmed by JPMorgan Chase & Co. in a report issued on Thursday.
Several other analysts also recently commented on the stock. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Wednesday, October 18th. UBS Group raised shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating and upped their price objective for the company from $35.04 to $35.85 in a report on Monday, November 27th. TheStreet raised shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Argus dropped their price objective on shares of GlaxoSmithKline to $40.00 and set a “buy” rating on the stock in a report on Thursday, November 30th. Finally, Cowen set a $38.00 price objective on shares of GlaxoSmithKline and gave the company a “hold” rating in a report on Monday, December 11th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have issued a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus target price of $38.57.
GlaxoSmithKline (NYSE GSK) traded up $0.66 during trading hours on Thursday, reaching $37.50. 4,989,600 shares of the company’s stock traded hands, compared to its average volume of 5,400,000. The stock has a market cap of $92,080.00, a P/E ratio of 28.85, a PEG ratio of 2.15 and a beta of 0.97. GlaxoSmithKline has a 12 month low of $34.52 and a 12 month high of $44.53. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%. research analysts anticipate that GlaxoSmithKline will post 2.9 earnings per share for the current fiscal year.
In other news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 10.00% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of GSK. Principal Financial Group Inc. acquired a new position in shares of GlaxoSmithKline in the 2nd quarter valued at $602,000. Coastline Trust Co acquired a new position in shares of GlaxoSmithKline in the 2nd quarter valued at $202,000. Dorsey & Whitney Trust CO LLC lifted its stake in shares of GlaxoSmithKline by 9.4% in the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 6,116 shares of the pharmaceutical company’s stock valued at $264,000 after purchasing an additional 526 shares during the period. King Luther Capital Management Corp lifted its stake in shares of GlaxoSmithKline by 1.0% in the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock valued at $234,000 after purchasing an additional 55 shares during the period. Finally, Comerica Securities Inc. lifted its stake in shares of GlaxoSmithKline by 22.0% in the 2nd quarter. Comerica Securities Inc. now owns 10,735 shares of the pharmaceutical company’s stock valued at $467,000 after purchasing an additional 1,933 shares during the period. Hedge funds and other institutional investors own 9.80% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/glaxosmithklines-gsk-neutral-rating-reaffirmed-at-jpmorgan-chase-co/1808501.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.